Why Liquidia Stock Was Diving This Week

Regardless, its one commercialized drug is doing well by any measure.

Liquidia (NASDAQ: LQDA) hasn't been the healthiest healthcare stock on the exchange over the past few days. On Wednesday, the commercial-stage biotech published a quarterly earnings report that led to a pronounced sell-off; as of early Friday morning, its shares were down by 20% week to date.

In its second quarter, Liquidia's revenue totaled almost $171.7 million, far higher than the $8.8 million it posted in the same period of 2025. That sharp rise was due almost entirely to increases in sales volume of the company's lone commercialized drug, the pulmonary hypertension treatment Yutrepia, which hit the market in June of that year.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »

On the bottom line, Liquidia flipped to a net profit under generally accepted accounting principles (GAAP) of $74.7 million ($0.74 per share), from the year-ago loss of $41.6 million.

Although the company edged past the consensus analyst estimate of just under $171 million, it slightly missed the $0.76-per-share net income forecast.

Liquidia updated the progress of its one remaining developmental program, that for L-606. This medication uses the same molecule as Yutrepia and targets the same affliction. However, it has a different formulation and delivery method.

That bottom-line miss barely counts as a miss at all, given its tiny size. What happened with Liquidia was that its stock had risen so steeply -- it was up 155% year-to-date prior to earnings -- that nothing short of a crushing, blowout quarter would have sustained the momentum.